Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
about
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsEmerging utility of once-weekly exenatide in patients with type 2 diabetesA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutideAdverse Effects of GLP-1 Receptor AgonistsCardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonistsBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingEffects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysisThe physiological role of the brain GLP-1 system in stressEfficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysisEffects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Cardiovascular effects of incretin therapy in diabetes care.Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.Incretin-based medications for type 2 diabetes: an overview of reviews.Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failureGlucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies.Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyLiraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III studyReview of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetesCardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetesLiraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-AnalysisExenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production.A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.
P2860
Q26749495-C3BF69FC-C3E0-4452-9427-BCBB17671EB0Q26777320-B9A90CC2-CB68-44C5-AF3C-7DADC02C0515Q26796417-2E8FE163-518F-4053-96CB-967ABF619786Q26801346-80DB2CD1-EB63-4287-B10B-A028CF88505BQ26823085-292C9BC2-B3E5-48C5-B457-B71DD002D5BAQ26992979-323BF0A7-8E89-45AB-A3A1-9983A5E5AA92Q27012696-40ABF6F3-C0EE-4E9D-839D-0843BCA0076AQ28077787-E3482B90-08D3-4D7B-ADA7-47521CE4DC0AQ31082841-AE2D5A39-66EB-4EA5-ACFD-13640906CABCQ33570239-57426145-2A0D-4269-831F-9753BFBAD9F3Q33708984-EE7AC361-B16C-4E84-9F86-29E49D3F36A6Q33824522-401DA1C9-4210-4D31-B309-9A5D42160E0FQ33993725-FA298B15-0B5F-45C2-9028-1468DEAD58C9Q34171759-DA3A7E23-BC4F-4FF9-A642-319FC2474236Q34264359-183C0260-61B3-4483-811B-BDC21D85DB99Q34509910-5FD78195-5194-435E-8870-89805D1627F2Q35044151-17563EC3-7677-4B40-92FD-620E368EAD5EQ35411439-12C89204-5D3D-4BB3-A796-C506928D9AC1Q35577601-179CD9FB-24D1-4578-9317-6A9295A20C55Q35654002-A89F2A75-52D4-4761-B4D1-721B26880C60Q36050559-37933B56-05BC-4A1D-9959-7C48DF9F46D5Q36069685-200DB720-483F-49B4-9FD5-AAEB7949B85EQ36220895-38364C24-0212-4B27-8927-EEB0EE23401FQ36302662-A1CF11D7-2E91-4A03-988A-729436EA85B3Q36406821-55C795D3-EBCD-43F2-B018-53A30C9E8044Q36454284-EFD5ECCE-E339-4007-B3CA-09ED43FA7066Q37108395-97394ACD-AA17-4571-ADBE-3F6F90739545Q37125983-B625E0F9-33C4-4DF5-90FE-A2483BFD3D05Q37223428-A0DFA6A2-1478-45A7-8912-4A085506D406Q37225065-EDAD5418-9BEB-4629-AD91-E682233A8420Q37295997-C5C87E52-B1EC-4878-9A18-1A7CAFF92800Q37340223-28545144-0984-46C1-8880-2A00DC598AABQ37561260-A276B734-145B-4488-A228-1A606570F12DQ37562586-31F94315-2B8C-42FD-8DE2-5E77318581DCQ37568754-C1550B59-37CE-4FDE-B156-AB9B1272E699Q37586881-D5DE0C71-11DB-476C-A136-A5C4C0F9C51DQ37631924-DA81DF9B-A42B-4D69-91B5-2052699E251CQ37639297-A614DC38-FF2F-46E5-9097-5880B1271BB0Q37686091-BF0559D9-72DE-43B8-8D98-0D1F3C190E3CQ37696559-EBAFE3DB-E3C5-4739-BB00-94BB35955AF3
P2860
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effects of exenatide and lirag ...... atic review and meta-analysis.
@ast
Effects of exenatide and lirag ...... atic review and meta-analysis.
@en
type
label
Effects of exenatide and lirag ...... atic review and meta-analysis.
@ast
Effects of exenatide and lirag ...... atic review and meta-analysis.
@en
prefLabel
Effects of exenatide and lirag ...... atic review and meta-analysis.
@ast
Effects of exenatide and lirag ...... atic review and meta-analysis.
@en
P2093
P2860
P1433
P1476
Effects of exenatide and lirag ...... matic review and meta-analysis
@en
P2093
Harpal S Randeva
Joseph P O'Hare
Louise E Robinson
Tim A Holt
P2860
P356
10.1136/BMJOPEN-2012-001986
P50
P577
2013-01-24T00:00:00Z